1. Introduction {#s0005}
===============

Dabigatran is a non-vitamin K antagonist oral anticoagulant that competitively and reversibly inhibits thrombin in a concentration-dependent manner and thereby reduces platelet aggregation ([@bb0170]). Dabigatran is administered as dabigatran etexilate (DE), the prodrug of dabigatran, which facilitates the gastrointestinal absorption, as dabigatran is a highly polar substance and therefore not available orally ([@bb0135]). The facilitation of gastrointestinal absorption is achieved by adding an ethyl group at the carboxylic acid group and a hexyloxycarbonyl side chain at the amidine group of dabigatran resulting in an absolute bioavailability of 6.5% after oral administration ([@bb0140], [@bb0135]). After oral administration, DE is rapidly hydrolysed to its active form, dabigatran, by non-specific ubiquitous esterases ([@bb0135]).

Thrombin is a trypsin-like serine protease that plays a key role in the coagulation cascade. However, it also affects other organ systems due to the presence of thrombin receptors (TRs) outside the vascular domains ([@bb0010], [@bb0125]). The TR is a seven transmembrane G-protein-coupled receptor that has been reported to be expressed, among others, in osteoblasts, macrophages, endothelial cells, and muscle cells ([@bb0010], [@bb0005], [@bb0150]). Thrombin has been reported to be synthesized and secreted by osteoclasts, in addition to the more abundant production in the liver ([@bb0065]). However, the physiological role of TR and thrombin on bone metabolism and bone morphology has not yet been fully elucidated.

It has been reported, that thrombin stimulates the expression of interleukin 6 (IL-6), prostaglandin E~2~ (PGE~2~) and cyclooxygenase 2 (COX-2) mRNA in osteoblasts ([@bb0070], [@bb0095]). IL-6 and PGE~2~ have been shown to increase the expression of RANKL relative to OPG ([@bb0035], [@bb0085]), resulting in a greater activation of osteoclasts and thereby a more rapid degradation of the mineralized bone matrix. This is consistent with the findings of [@bb0150] who recently reported that TR deficiency leads to a high bone mass phenotype due to a reduction in RANKL and an upregulation of OPG secretion from osteoblasts leading to a decreased RANKL/OPG ratio in male mice. However, they also reported preliminary findings in female TR deficient mice showing no influence on either trabecular or cortical bone. Moreover, [@bb0015] reported that TR knock-out female mice had decreased bone mass and compromised bone architecture. Taken together these finding indicate that thrombin deficiency may influence the skeleton in female and male mice differently.

Thrombin also plays a role in direct cleavage of the bone protein osteopontin ([@bb0110]), which is primarily produced by osteoblasts ([@bb0050]), and is important for anchoring osteoclasts to the mineral matrix of bones ([@bb0105], [@bb0110], [@bb0120]).

A recent study published in abstract form only has indicated that DE-induced inhibition of thrombin in C57BL/6 mice, resulted in significantly increased femoral aBMD as well as trabecular BV/TV ([@bb0060]).

Therefore, the aim of the present study was to investigate whether DE can increase aBMD, bone strength, bone formation, and bone microstructure in healthy female and male mice, and to investigate whether the effect of DE on bone is sex-dependent.

2. Materials and methods {#s0010}
========================

2.1. Animals and study design {#s0015}
-----------------------------

The study comprised twenty-four female and twenty-eight male 14-week-old C57BL/6JBomTac mice (Taconic, Denmark). Female and male mice were stratified according to their body weight (BW), which were 22.48 g ± 0.90 g and 27.61 g ± 2.68 g, respectively. The mice were divided into the following four subgroups: 1. Control (Ctrl) 3 weeks; 2. DE 3 weeks; 3. Ctrl 6 weeks; 4. DE 6 weeks and subsequently allowed three full days of acclimatization to adapt to the new surroundings before the study begun. The animals were housed in cages equipped with laboratory animal bedding material, nesting material (SizzleNest, Scanbur, Denmark), and environmental enrichment devices. The female mice were housed with 3 mice per cage, and the male mice were housed with 4, 5, or 7 mice per cage. The cages were stored at room temperature (21 °C and approximately 30% humidity) with 12 h light/12 h dark cycles.

All mice were given either placebo-chow or DE-chow (BIBR1048MS 15 mg DE/g ([@bb0130])) and water ad libitum. A recent study by [@bb0060] used a relatively high dosage of DE, and we therefore chose a DE dose that resulted in a plasma dabigatran concentration in the same range as Kalinowski et al. in order to detect any positive or negative effects of DE on bone tissue. The DE-chow was the same as the placebo-chow with DE added. Both chows were provided by Boehringer Ingelheim, Germany. New chow was offered every Monday, Wednesday, and Friday and any leftover chow were removed from the cages and weighed using a digital scale (Mettler AT250, Mettler Instrumente AG, Greifensee, Switzerland) in order to monitor daily food intake. During replacement of chow, the mice were assessed for visible spontaneous bleedings. Finally, all mice were weighed once a week and at the end of the study using the digital scale.

All animals were injected s.c. with calcein (20 mg/kg) and tetracycline (20 mg/kg) 8 and 4 days prior euthanization, respectively.

Before euthanization, the animals were anaesthetized by inhalation of 4% isoflurane (IsoFlo Vet, Orion Pharma, Abbott). Blood was drawn from the inferior vena cava, and the heart removed to ensure euthanization. Tibia, femur, and a segment of the columna consisting of vertebras Th13-L5 were removed for later investigations. Tibial and femoral lengths were measured using a digital caliper. The right tibiae and femora and the column vertebra segments were stored at −29 °C in Ringer\'s solution, while the left tibiae and femora, were fixed in 4% formaldehyde.

The study complied with the guiding principles in the European Communities Council Directive of 24 November 1986 (86/609/EEC), and was approved by the Danish Animal Experiments Inspectorate (2012-15-2934-00769).

2.2. Peripheral dual energy X-ray absorptiometry (pDEXA) {#s0020}
--------------------------------------------------------

Tibiae, femora, and the vertebral segments were scanned in a pDEXA scanner (Sabre XL, Norland Stratec, Pforzheim, Germany) at a pixel size of 0.1 mm × 0.1 mm and a scan speed of 3.0 mm/s as previously described in detail ([@bb0075]).

The coefficient of variation of femoral aBMD determined with pDEXA is 2.8% in our laboratory (same sample measured 10 times).

2.3. Micro-computed tomography (μCT) {#s0025}
------------------------------------

Prior to μCT scanning, L4 was carefully separated from the vertebral segment, soft tissue removed, and corpus vertebra isolated. The scanning was performed using a desktop μCT scanner (μCT 35, Scanco Medical AG, Switzerland). The distal femoral epiphyses and metaphyses were both scanned, as site specific trabecular changes has previously been reported ([@bb0160]). Tibiae, femora, and L4s were scanned at different sessions with different settings. The distal femoral epiphysis and metaphysis, proximal tibial epiphysis, and L4 were scanned with 1000 projections/180° at an isotropic voxel size of 3.5 μm, an X-ray tube voltage of 55 kVp, a current of 145 μA, and an integration time of 800 ms. The tibial and femoral mid-diaphyses were scanned with 500 projections/180°, at an isotropic voxel size of 7.0 μm, an X-ray tube voltage of 55 kVp, a current of 145 μA, and an integration time of 300 ms.

Subsequently, volumes of interest (VOIs) were semi interactively drawn using the software provided with the μCT scanner for data evaluation (μCT Evaluation V6.5-1, Scanco Medical AG, Switzerland). The femoral epiphyseal VOI started at the point where the lateral and medial epicondyle fused to one coherent structure and ended where the growth plate first appeared, and contained trabecular bone only. The distal femoral metaphyseal VOI and proximal tibial metaphyseal VOI both started 200 μm below the point where the mineralized cartilage from the growth plate fused and ended 1000 μm further below, and contained trabecular bone only ([Fig. 1](#f0005){ref-type="fig"}). The L4 vertebral VOI was defined as the whole trabecular network from upper to lower growth plate. Finally, the VOIs at the tibial and femoral mid-diaphysis were selected as a 0.82-mm-high region centred on the mid-point (50%) of the bone, thus containing cortical bone only ([Fig. 1](#f0005){ref-type="fig"}). Dimensions of the femoral mid-diaphysis are reported as average cross-sectional areas determined as volumes divided by the height of the VOI.Fig. 1Micro-computed tomography (μCT) scans of a mouse femur, tibia, and vertebra L4. a: Green area represents analyzed volume of interest (VOI) of the femoral mid-diaphysis consisting of cortical bone only. b: Blue area represents analyzed VOI of the trabecular bone at the distal femoral metaphysis; red area represents analyzed VOI of the trabecular bone at the distal femoral epiphysis. c: Purple area represents analyzed VOI of the tibial mid-diaphysis consisting of cortical bone only. d: Orange area represents analyzed VOI of the trabecular bone at the proximal tibial metaphysis. e: Grey area represents analyzed VOI of vertebra L4 consisting of trabecular bone only.Fig. 1

The data were low-pass filtered using a Gaussian filter (σ = 0.8 and support = 1) and segmented with a fixed threshold filter. The threshold was determined automatically with IPL (v. 5.11, Scanco Medical AG, Switzerland) as the minimum point between marrow and bone peak in the attenuation histogram, for at least three samples from each group and the median value was used as threshold for evaluation of all samples. The thresholds for evaluation of female mice data were: Femoral epiphysis and metaphysis and tibial metaphysis: 525.5 mg HA/cm^3^; femoral diaphysis: 550.2 mg HA/cm^3^; tibial diaphysis: 556.4 mg HA/cm^3^; and L4: 519.4 mg HA/cm^3^. The thresholds for evaluation of male mice data were: Femoral epiphysis and metaphysis and tibial metaphysis: 519.4 mg HA/cm^3^; femoral diaphysis: 556.4 mg HA/cm^3^; tibial diaphysis: 562.5 mg HA/cm^3^: and L4: 519.4 mg HA/cm^3^. The assessment of the bone microstructure using μCT was performed in accordance with the current guidelines ([@bb0030]).

The coefficient of variation of distal femoral metaphyseal BV/TV determined with μCT is 1.8% in our laboratory (same sample measured 10 times).

2.4. Mechanical testing {#s0030}
-----------------------

Mechanical properties of femora, tibiae, and L4 were determined with femoral neck test, femoral and tibial 3-point bending test, and vertebral compression test, respectively. Different site specific bone tests were used, as treatment with bone acting agents have been shown to exhibit site specificity of the mechanical properties ([@bb0080]).

The mechanical integrity of the cortical bone at the tibial and femoral mid-diaphyses was determined using a 3-point bending test as previously described in detail ([@bb0055]). The tibiae or femora were placed on two supporting bars separated by either 10.33 mm (tibia) or 7.14 mm (femur) in a material testing machine (Instron model 5566, United Kingdom). Vertical load was applied using a third rounded bar at a constant deflection rate of 2 mm/min at the mid-diaphysis until fracture was achieved.

Femoral neck test was performed by placing the remaining proximal femur in a custom-made fixation device supporting the bone shaft while exposing the neck and applying vertical load to the top of the femoral head at a constant deflection rate of 2 mm/min until fracture ([@bb0055]).

Finally, the L4 was compression tested by placing it in the materials testing machine, stripped from any cartilage remains and intervertebral discs, and vertical load was applied with a steel cylinder at a deflection rate of 2 mm/min until fracture ([@bb0165]).

During the mechanical testing data was recorded and stored with Merlin v. 3.21 (Instron, United Kingdom) and subsequently analyzed with a custom-made computer program.

2.5. Dynamic bone histomorphometry {#s0035}
----------------------------------

After the mechanical test of the tibial mid-diaphysis, the region just above the fracture site of the proximal part of the tibial mid-diaphysis was used for dynamic bone histomorphometry. Two approximately 200-μm-thick cross-sectional slices were sawed with a diamond parallel precision saw (EXAKT Apparatebau, Germany) and mounted with Pertex on glass slides.

The fluorescent labels were detected using a light microscope equipped for fluorescence light (Nikon Eclipse i80, Japan). Live images of the slides were shown on a computer screen and analyzed with NewCAST (Visiopharm NewCAST v. 4.6.3.857, Denmark). A randomly rotated star-shaped grid with 24 radiating arms was used to count intersections with bone labels at the periosteal and endosteal bone surfaces ([@bb0075]). The centre of the grid was placed in the centre of the medullar cavity, so that the arms of the grid randomly intersected the endosteal and periosteal bone surfaces. The distances between calcein and tetracycline labels were measured using the integrated measuring tool in the stereology software. All dynamic bone histomorphometry measurements were performed in a blinded fashion.

MS/BS were calculated as the number of intersections with calcein and tetracycline labels (double labels) plus half the number of intersections with either calcein or tetracycline (single labels) divided by the total number of intersections with an intact bone surface. Mineral apposition rate (MAR) was calculated as the average distance between calcein and tetracycline labels divided by the inter-labelling period of 4 days. Bone formation rate per bone surface (BFR/BS) was calculated as MS/BS × MAR. MS/BS, MAR, and BFR/BS of the cortical bone were determined at a magnification of × 1190. In addition, osteoclast covered surfaces (Oc.S/BS) were estimated in a similar way using proximal tibial sections stained for Cathepsin K as described in details by [@bb0155]. Osteoclasts were defined as Cathepsin K-positive cells with at least one nucleus situated at the bone surface at a final magnification of × 1190.

The coefficient of variation of tibial fluorochrome labels determined with dynamic bone histomorphometry is 10.6% in our laboratory (same sample measured 10 times).

2.6. Blood serum analysis {#s0040}
-------------------------

Blood samples were kept in 5 ml heparinized Eppendorf tubes on ice for 15 min, centrifuged for 10 min at 4000*g*, and stored at −80 °C for the subsequent analyses.

In order to determine the plasma concentration of dabigatran, the diluted thrombin time (dTT) was compared with a standard curve generated by measuring TT of normal mouse plasma containing known concentrations of dabigatran. Before determination of dTT, heparin in the samples was neutralized by heparinase, and replaced by sodium citrate. Furthermore, it was controlled that this replacement did not influence dTT.

2.7. Statistical analysis {#s0045}
-------------------------

Data are given as mean ± SD, and differences were considered significant at *p* \< 0.05. Statistical analysis was performed with SigmaPlot v. 12.5 (Systat Software, USA). An asterisk denotes a significant difference (*p* \< 0.05) for the effect of DE using two-way ANOVA followed by a Holm-Sidak post hoc test.

A priori power calculations (power = 0.8) on healthy C57BL/6JBomTac mice showed that a 7% difference in aBMD (CV: 3%) can be demonstrated between groups with *n* = 6 animals.

3. Results {#s0050}
==========

3.1. Food consumption, body weight, and length of tibia and femur {#s0055}
-----------------------------------------------------------------

On average female and male mice consumed the same amount of chow per day regardless of whether they were served placebo or DE enriched chow. In addition, the food consumption did not differ between 3- and 6-weeks groups or between the first and second half of the study ([Table 1](#t0005){ref-type="table"}). The daily mean dose of DE was 1.70 mg DE/g BW and 1.52 mg DE/g BW for female and male mice, respectively.Table 1Final number of animals, chow consumption, and start and final body weight (BW) of female and male mice treated with either placebo or DE for 3 or 6 weeks, respectively. Mean (SD). ^⁎^*p* \< 0.05 vs. start BW.Table 1FemaleMaleFinal no. of animalsChow consumption (g/day)Start BW (g)Final BW (g)Final no. of animalsChow consumption (g/day)Start BW (g)Final BW (g)Ctrl 3 weeks62.30 (1.25)22.50 (0.79)22.60 (1.46)72.30 (0.95)27.44 (3.11)25.79^⁎^ (2.02)DE 3 weeks62.60 (0.94)22.4 (1.17)23.07 (1.38)72.20 (0.81)28.00 (1.94)24.76^⁎^ (0.73)Ctrl 6 weeks62.80 (0.17)22.47 (1.03)23.03 (1.19)73.30 (1.28)27.19 (3.40)25.07^⁎^ (2.76)DE 6 weeks62.70 (0.16)22.55 (0.80)23.25^⁎^ (0.03)73.10 (0.62)27.80 (2.30)25.16^⁎^ (1.75)

The start BW did not differ between the DE-groups and the control groups for either female or male mice. Female DE mice increased their BW significantly (*p* = 0.018) after 6 weeks, whereas the initial BW did not differ from the final BW in any of the other female mice. In contrast, all male mice lost approximately 10% (*p* = 0.014) of their BW during the first week, after which the BW stabilized. In male mice, the final BW was significantly lower in all groups compared to their initial BW. DE had no effect on BW in either female or male mice compared to controls ([Table 1](#t0005){ref-type="table"}).

In female mice, the plasma levels of dabigatran were 933 ± 121 ng/ml and 1143 ± 650 ng/ml after 3 and 6 weeks, respectively. In male mice, the plasma levels of dabigatran were 1305 ± 389 ng/ml and 2365 ± 787 ng/ml after 3 and 6 weeks, respectively. Despite the relatively high plasma levels of dabigatran, no bleeding episodes were detected, and no animals died prematurely during the study.

The femoral or tibial length did not differ between DE and control groups, indicating that DE had no effect on longitudinal bone growth at these two skeletal sites ([Table 2](#t0010){ref-type="table"}).Table 2Tibial and femoral length and tibial, femoral and vertebral (Th13-L5) BMC (bone mineral content) in female and male mice treated with either placebo or DE for 3 or 6 weeks, respectively. Mean (SD).Table 2FemaleMaleTibial length (mm)Femoral length (mm)Tibial BMC (mg)Femoral BMC (mg)Vertebral BMC (mg)Tibial length (mm)Femoral length (mm)Tibial BMC (mg)Femoral BMC (mg)Vertebral BMC (mg)Ctrl 3 weeks17.79 (0.18)15.25 (0.24)152 (23)189 (15)315 (13)17.69 (0.30)15.42 (0.35)174 (28)204 (24)313 (26)DE 3 weeks17.86 (0.18)15.32 (0.29)168 (24)197 (11)314 (24)17.61 (0.27)15.19 (0.28)166 (21)183 (20)290 (20)Ctrl 6 weeks17.73 (0.32)15.02 (0.37)155 (25)185 (15)290 (19)17.69 (0.39)15.44 (0.48)167 (18)197 (15)304 (30)DE 6 weeks17.76 (0.33)15.30 (0.17)170 (16)197 (12)314 (23)17.80 (0.22)15.48 (0.16)175 (19)191 (16)282 (69)

3.2. Peripheral dual energy X-ray absorptiometry (pDEXA) {#s0060}
--------------------------------------------------------

Female mice treated with DE had significantly higher tibial aBMD (two-way ANOVA: *p* \< 0.05), and resulted in an 8.6% increase after 6 weeks of intervention (*p* \< 0.05) compared to controls. Intervention with DE also tended to increase tibial BMC, however, this did not reach the level of significance (two-way ANOVA: *p* = 0.099). No differences in aBMD or BMC were observed in either the segment of column vertebrae or femur in female mice.

DE did not affect aBMD or BMC in male mice at any of the investigated skeletal sites ([Fig. 2](#f0010){ref-type="fig"} and [Table 2](#t0010){ref-type="table"}).Fig. 2Areal bone mineral density (aBMD) in female and male mice treated with either placebo or DE for 3 or 6 weeks (w), respectively. Comparison between groups was made using a two-way ANOVA with a post hoc Holm Sidak test. An \* denotes significant differences (*p* \< 0.05) between DE and controls.Fig. 2

3.3. Micro-computed tomography (μCT) {#s0065}
------------------------------------

### 3.3.1. Cortical bone {#s0070}

Intervention with DE resulted in a larger bone area (two-way ANOVA: *p* \< 0.05) and tissue area (two-way ANOVA: *p* \< 0.05) of the tibial mid-diaphysis in female mice. After 6 weeks of DE intervention diaphyseal bone area increased by 6.72% (*p* \< 0.05) and tissue area increased by 5.91% (*p* \< 0.05) compared to controls, whereas DE did not influence either tibial marrow area or cortical thickness in female mice ([Fig. 3](#f0015){ref-type="fig"}) ([Table 3](#t0015){ref-type="table"}).Fig. 3Cortical bone parameters in female and male mice treated with either placebo or DE for 3 or 6 weeks (w), respectively. (a) Tibial bone area. (b) Tibial tissue area. (c) Tibial marrow area. (d) Tibial cortical thickness (Ct.Th). An \* denotes significant differences (*p* \< 0.05) between DE and controls.Fig. 3Table 3Femoral and vertebral cortical and trabecular bone parameters in female and male mice treated with either placebo or DE for 3 or 6 weeks, respectively. B.Ar: bone area, Ma.Ar: marrow area, T.Ar: tissue area, Ct.Th: cortical thickness, pMOI: polar moment of inertia, BV/TV: bone volume/tissue volume, Tb.Th: trabecular thickness, Tb.Sp: trabecular spacing and SMI: structure model index, CD: connectivity density. Mean (SD).Table 3Femoral diaphyseal cortical bone parametersFemaleMaleB.Ar (mm^2^)T.Ar (mm^2^)Ma.Ar (mm^2^)Ct.Th (mm)pMOI (mm^4^)B.Ar (mm^2^)T.Ar (mm^2^)Ma.Ar (mm^2^)Ct.Th (mm)pMOI (mm^4^)Ctrl 3 weeks0.729 (0.031)1.835 (0.059)1.106 (0.055)0.165 (0.007)0.357 (0.028)0.810 (0.099)1.997 (0.205)1.187 (0.108)0.175 (0.013)0.438 (0.090)DE 3 weeks0.751 (0.026)1.905 (0.069)1.154 (0.055)0.164 (0.006)0.387 (0.030)0.780 (0.061)1.936 (0.170)1.157 (0.119)0.173 (0.008)0.407 (0.070)Ctrl 6 weeks0.699 (0.050)1.827 (0.110)1.129 (0.076)0.158 (0.009)0.346 (0.043)0.730 (0.079)1.898 (0.214)1.168 (0.147)0.162 (0.011)0.379 (0.077)DE 6 weeks0.737 (0.023)1.848 (0.052)1.112 (0.039)0.166 (0.004)0.366 (0.065)0.741 (0.047)1.938 (0.120)1.197 (0.083)0.161 (0.008)0.397 (0.047)  Femoral metaphyseal trabecular bone parametersFemaleMaleBV/TVTb.Th (mm)Tb.Sp (mm)SMICD (mm^− 3^)BV/TVTb.Th (mm)Tb.Sp (mm)SMICD (mm^− 3^)Ctrl 3 weeks0.070 (0.014)0.032 (0.002)0.270 (0.022)1.881 (0.155)188 (44.3)0.145 (0.032)0.039 (0.004)0.202 (0.015)1.246 (0.368)306 (59.4)DE 3 weeks0.056 (0.017)0.031 (0.002)0.291 (0.024)0.291 (0.024)150 (48.5)0.139 (0.020)0.039 (0.003)0.197 (0.013)0.291 (0.024)320 (23.5)Ctrl 6 weeks0.047 (0.013)0.032 (0.003)0.306 (0.016)2.313 (0.259)102 (11.6)0.117 (0.016)0.038 (0.004)0.218 (0.008)1.527 (0.147)227 (22.2)DE 6 weeks0.056 (0.012)0.035 (0.003)0.300 (0.019)2.189 (0.224)108 (17.2)0.118 (0.019)0.038 (0.003)0.217 (0.006)1.521 (0.219)223 (14.2)  Femoral epiphyseal trabecular bone parametersFemaleMaleBV/TVTb.Th (mm)Tb.Sp (mm)SMICD (mm^− 3^)BV/TVTb.Th (mm)Tb.Sp (mm)SMICD (mm^− 3^)Ctrl 3 weeks0.223 (0.019)0.053 (0.004)0.246 (0.022)0.112 (0.151)194 (29.9)0.287 (0.085)0.052 (0.008)0.180 (0.008)− 0.068 (0.806)319 (48.3)DE 3 weeks0.213 (0.016)0.053 (0.004)0.253 (0.017)0.221 (0.109)187 (20.1)0.306 (0.011)0.052 (0.002)0.172 (0.002)− 0.249 (0.072)359 (19.2)Ctrl 6 weeks0.216 (0.012)0.053 (0.003)0.250 (0.021)0.172 (0.035)178 (14.6)0.278 (0.023)0.050 (0.004)0.178 (0.004)− 0.000 (0.164)323 (28.7)DE 6 weeks0.22 (0.013)0.055 (0.003)0.242 (0.021)0.153 (0.021)167 (21.7)0.283 (0.026)0.050 (0.002)0.176 (0.002)− 0.084 (0.183)336 (28.1)  Tibial metaphyseal trabecular bone parametersFemaleMaleBV/TVTb.Th (mm)Tb.Sp (mm)SMICD (mm^− 3^)BV/TVTb.Th (mm)Tb.Sp (mm)SMICD (mm^− 3^)Ctrl 3 weeks0.064 (0.019)0.037 (0.004)0.298 (0.027)2.056 (0.281)80.7 (26.9)0.139 (0.026)0.043 (0.004)0.193 (0.020)1.718 (0.237)198 (63.6)DE 3 weeks0.052 (0.008)0.037 (0.002)0.322 (0.021)2.154 (0.154)62.1 (19.7)0.125 (0.017)0.040 (0.003)0.189 (0.022)1.861 (0.150)197 (35.4)Ctrl 6 weeks0.050 (0.012)0.039 (0.003)0.333 (0.037)2.301 (0.302)49.3 (22.1)0.123 (0.022)0.040 (0.004)0.199 (0.015)1.806 (0.235)160 (26.7)DE 6 weeks0.054 (0.011)0.042 (0.003)0.350 (0.040)2.180 (0.115)46.9 (6.55)0.125 (0.036)0.040 (0.004)0.198 (0.023)1.827 (0.332)183 (75.6)  Vertebral trabecular bone parametersFemaleMaleBV/TVTb.Th (mm)Tb.Sp (mm)SMICD (mm^− 3^)BV/TVTb.Th (mm)Tb.Sp (mm)SMICD (mm^− 3^)Ctrl 3 weeks0.155 (0.009)0.034 (0.002)0.240 (0.009)0.404 (0.070)485 (143)0.194 (0.026)0.035 (0.003)0.183 (0.008)0.335 (0.200)891 (174)DE 3 weeks0.154 (0.018)0.034 (0.002)0.242 (0.014)0.496 (0.159)428 (83.4)0.180 (0.013)0.033 (0.002)0.187 (0.008)0.477 (0.123)798 (181)Ctrl 6 weeks0.147 (0.020)0.034 (0.002)0.251 (0.014)0.607 (0.201)426 (42.9)0.176 (0.014)0.033 (0.003)0.187 (0.008)0.505 (0.081)672 (131)DE 6 weeks0.157 (0.014)0.036 (0.002)0.247 (0.016)0.525 (0.082)360 (70.9)0.179 (0.022)0.033 (0.003)0.186 (0.011)0.448 (0.129)588 (125)

Finally, DE had no effect on any of the femoral or tibial cortical bone parameters in male mice, or any effect on femoral cortical bone parameters in female mice.

### 3.3.2. Trabecular bone {#s0075}

DE had no effect on the trabecular bone parameters at the femoral epiphysis or metaphysis, the tibial metaphysis, or the L4 in either female or male mice ([Table 3](#t0015){ref-type="table"}).

3.4. Mechanical testing {#s0080}
-----------------------

The tibial 3-point bending test showed that DE significantly increased fracture strength for female mice (two-way ANOVA: *p* \< 0.05) compared to Ctrl ([Fig. 4](#f0020){ref-type="fig"}). DE did not affect bone strength at the femoral mid-diaphysis, femoral neck, or L4 in female mice.Fig. 4Mechanical test of female and male mice treated with either placebo or DE for 3 or 6 weeks (w), respectively. (a) Tibial 3-point bending test. (b) L4 compression test. (c) Femoral 3-point bending test. (d) Femoral neck test.Fig. 4

DE did not influence either tibial or femoral bone fracture strength in male mice.

3.5. Dynamic bone histomorphometry and osteoclast covered bone surfaces {#s0085}
-----------------------------------------------------------------------

DE did not influence MS/BS, MAR, BFR/BS, and Oc.S/BS in either female or male mice ([Table 4](#t0020){ref-type="table"}).Table 4Tibial dynamic bone histomorphometry in female and male mice treated with either placebo or DE for 3 or 6 weeks, respectively. MS/BS: mineralizing surface/bone surface, MAR: mineral apposition rate and BFR/BS: bone formation rate/bone surface, Oc.S/BS: osteoclast covered surfaces. Mean (SD).Table 4Endosteal surfaceFemaleMaleMS/BS (%)MAR (μm/day)BFR/BS (μm/day)Oc.S/BS (%)MS/BS (%)MAR (μm/day)BFR/BS (μm/day)Oc.S/BS (%)Ctrl 3 weeks5.1 (4.7)0.013 (0.012)0.001 (0.002)0.58 (0.70)9.9 (10.6)0 (0)0 (0)1.55 (1.07)DE 3 weeks8.3 (5.5)0.021 (0.014)0.002 (0.002)2.50 (1.91)5.6 (9.6)0 (0)0 (0)1.11 (1.11)Ctrl 6 weeks17.5 (21.0)0.044 (0.052)0.017 (0.034)3.94 (3.02)8.3 (5.1)0 (0)0 (0)2.92 (1.92)DE 6 weeks22.2 (22.5)0.055 (0.056)0.023 (0.042)2.78 (1.16)13.4 (11.6)0.066 (0.17)0.012 (0.032)2.46 (1.99)  Periosteal surfaceFemaleMaleMS/BS (%)MAR (μm/day)BFR/BS (μm/day)MS/BS (%)MAR (μm/day)BFR/BS (μm/day)Ctrl 3 weeks1.3 (1.3)0.003 (0.003)1 × 10^− 4^ (9 × 10^− 5^)5.6 (9.6)0 (0)0 (0)DE 3 weeks0.5 (0.6)0.001 (0.002)0.000 (1.61 × 10^− 5^)3.1 (7.1)0 (0)0 (0)Ctrl 6 weeks2.0 (1.9)0.005 (0.005)2 × 10^− 4^ (2.04 × 10^− 4^)1.18 (1.8)0 (0)0 (0)DE 6 weeks1.4 (2.4)0.004 (0.006)2 × 10^− 4^ (4.31 × 10^− 4^)5.4 (2.6)0.076 (0.20)0.006 (0.016)

4. Discussion {#s0090}
=============

The present study demonstrated that DE administrated orally had a weak positive and site specific effect on bone in female mice and no positive effect on bone in male mice.

The effect of thrombin and the thrombin receptor in relation to bone have been investigated in both in vitro and in vivo experiments ([@bb0090], [@bb0120], [@bb0170]). In vitro studies of cell cultures have shown that thrombin can increase the expression of RANKL relatively to OPG mediated by IL6 and PGE~2~, thereby enhancing osteoclast activation and bone degeneration ([@bb0070], [@bb0095]). Therefore, it is reasonable to assume that inhibition of thrombin will result in a higher bone mass. This assumption has been investigated in thrombin receptor knockout (KO) C57BL/6 mice, which exhibited a decreased RANKL/OPG ratio and higher bone mass phenotype ([@bb0150]).

The outcome of previous in vivo studies of the effect of DE on rodent bone has been contradicting. In a study comparing the impact of DE and warfarin on bone structure, [@bb0040] investigated three different bone sites (tibia, femur, and vertebra) using bone histomorphometry. They studied female Sprague-Dawley rats given 1.0 mg DE/g chow for 6 weeks and found that DE did not influence trabecular bone microstructural parameters such as BV/TV, Tb.Th, or Tb.Sp, and had no effect on either MS/BS or BFR/BS. In the present study, we found that DE weakly increased tibial aBMD as well as tibial cortical bone area and tissue area in female mice, and that this was accompanied by increased tibial bone strength. In contrast, no effect of DE was seen in femur or L4 for any bone parameter investigated, and no effect of DE was detected on dynamic histomorphometry and the 3D trabecular microstructure at any of three bone sites investigated. However, it should be noted that the concentration of DE in the chow used in the present study was 15 mg/g and resulted in a mean dabigatran plasma concentration of 1143 ng/ml, whereas [@bb0040] used a diet with a DE concentration of 1 mg/g and reported a mean dabigatran plasma concentration of 150 ng/ml. Therefore, a possible reason for the different outcome of the two studies could be the 15 times higher DE dosage used in the present study, which resulted in an almost 8 times higher dabigatran plasma concentration.

Although a week positive effect of DE was seen in female mice in tibial bone, no significant effect of DE was seen in other parameters in female mice or in any parameter in male mice. However, as the only significant effect of DE was observed in tibial cortical bone in female mice, we cannot exclude that the minor, but significant, effect of DE on tibial cortical bone was a result of a statistical type-1 error. On the other hand the minor, but significant, effect of DE was observed for three different properties i.e. aBMD, outer cortical bone dimensions, and cortical bone fracture strength, which make the probability of a type-1 error less likely.

The findings of the present study are in contrast to findings reported in an abstract by [@bb0060]. They investigated 8-week-old C57BL/6 male mice treated with 8.5 mg/kg DE twice daily, given as i.p. injections for 6 weeks, and found a significant increase of 71% in femoral trabecular BV/TV, but no change in cortical bone mass ([@bb0060]). These findings were accompanied by an increase in serum P1NP and a decrease in serum CTX. No data on dabigatran plasma levels was given. However, according to [@bb0175], a dosage of 9 mg/kg BW of DE administered i.p. to C57BL/6 male mice results in a maximum dabigatran plasma level of approximately 1200 ng/ml during the first hours after injection, and a dabigatran plasma level below 200 ng/ml 4 h after injection. In the present study, the dabigatran plasma levels of male mice fed DE chow was 1305 ng/ml and 2365 ng/ml after 3 and 6 weeks, respectively. Although, it cannot be precluded, a difference in DE concentration is probably not the most likely explanation for the discrepancies between the study by [@bb0060] and the present study. When DE is administered i.p., peak plasma dabigatran concentration will appear in spikes after each successive injection as shown by [@bb0175], in contrast to when DE is administered in the chow, which will result in a more stable dabigatran concentration. It is possible that spikes in dabigatran plasma concentration is necessary in order to generate the positive bone effect -- similar to what is seen with PTH ([@bb0020]). In order to detect any positive or negative effects of DE on bone tissue the present study used same intervention time of 6 weeks as the study by [@bb0060] and [@bb0040]. However, no studies have investigated the effect of DE on bone tissue in a dose-dependent manner, and therefore no optimal duration of intervention or dosage reference exists.

Previous in vivo studies of KO mice have suggested both sex- and bone dependent effects of DE. [@bb0150] reported that thrombin receptor deficiency leads to a high femoral bone mass phenotype in male C57BL/6 thrombin receptor KO mice, while no effect was seen in female mice. In contrast, [@bb0015] reported lowered tibial BV/TV and BMD in female C57BL/6 thrombin receptor KO mice. However, no previous study has compared the skeletal response in both sexes in the same study. In addition, [@bb0150] and [@bb0015] used KO mice, while the present study used drug induced inhibition of the thrombin receptor. The differences in study design make it difficult to compare the present study to the studies performed by [@bb0150] and [@bb0015] on KO mice. However, both the present study and the KO mice studies suggest that sex- and bone dependency might be present.

Oral anti-coagulants are widely used in the prevention and treatment of arterial and venous thrombo-embolic diseases, cardiovascular diseases such as deep vein thrombosis, and atrial fibrillation (chest guidelines ([@bb0045])), and for many cases treatment should be continued for many years ([@bb0045]). Some of the most frequently used anti-coagulants are vitamin K antagonist such as warfarin and phenprocoumon ([@bb0045]), which inhibits the γ-carboxylation of glutamatic acid residues of factor II, VII, IX, and X in the coagulation cascade. In clinical studies, warfarin has been associated with increased risk of rib and vertebral fractures ([@bb0145]), whereas data have been conflicting when it comes to whether warfarin treatment lead to decreased BMD ([@bb0115]). In rodent studies, warfarin treatment has been shown to have negative effects on bone i.e. decreased BV/TV, decreased bone strength and ultimate stress ([@bb0040], [@bb0115], [@bb0145]). In this context, it is should be emphasized that even with a fairly high dosage of DE no deleterious effects on bone structure or bone strength were found in the present study.

The doses used in the present study resulted in dabigatran plasma levels, which were 10--20 times higher than the dabigatran plasma concentrations used for prevention of non-valvular atrial fibrillation. In the RE-LY trial, the efficacy of DE to prevent stroke and systemic embolism was compared to warfarin in patients with atrial fibrillation ([@bb0025]). High dose DE, 150 mg twice daily, resulted in dabigatran mean plasma levels of 175 ng/ml and 91 ng/ml 1--3 h and 10--16 h after oral administration, respectively ([@bb0100]). Therefore, even though no reference guide exists for dabigatran plasma concentrations in relation to its effect on bone tissue, it is fair to say that a high plasma concentration was assured in the present study. When the weak bone effect of the relatively high DE plasma concentrations obtained in the present study is taken into consideration, it seems unlikely that a more pronounced bone effect will occur at lower plasma concentrations.

A limitation of the study was the unexpected loss of BW observed in male mice during the first week of the study, after which the loss of BW ceased. In contrast, no loss of BW was seen in female mice. The reason for this loss of BW around week 1 could be explained by a lower consumption of chow during the first half of the study compared to the last half. Furthermore, greater variations in aBMD standard derivations were found in the present study than what was expected a priori, suggesting a larger number of animals in each group should be considered for future studies. However, given the results from the present study it seems unlikely that DE exerts a general positive effect on bone tissue and that the overall results would be different if more animals were included in each group, even though it cannot completely be precluded.

In conclusion, DE may induce a site specific weak increase of tibial aBMD, tibial cortical bone area, tibial tissue area, and tibial bone strength in female mice, whereas no effect was found in femoral or vertebral bone, moreover, no positive bone effects were found in male mice. Importantly, no major deleterious effects of DE on bone tissue were seen despite the relatively high dose of DE used.
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